# US 2026/0077043 A1 · Combination therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0077043 A1
- Document ID: US20260077043A1
- Status: Published application
- Kind: A1
- Application number: 18/993,300
- Filed: 2023-07-12
- Published: 2026-03-19
- Earliest claimed: 2022-07-12
- Assignees: Leap Therapeutics, Inc.
- Applicants: Leap Therapeutics, Inc.
- Inventors: Michael H. Kagey; Cynthia A. Sirard; Michael Haas
- Web page: https://patentgrep.com/patent/US20260077043A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- C07K 16/18: against material from animals or humans
- A61K 31/282: Platinum compounds
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods of treating colorectal cancer in a subject in need thereof. The methods comprising co-administering to the subject: a) a DKK1 antibody, or antigen binding-fragment thereof; b) a VEGF or VEGFR inhibitor; and c) optionally one or more chemotherapeutic agents or a pharmaceutically acceptable salt of any of the foregoing, in an effective amount. The present invention also provides a pharmaceutical composition and a kit comprising a combination of a DKK1 antibody, and a VEGF or VEGFR inhibitor and optionally one or more chemotherapeutic agents.

## Claims

### Claim 1

A method of treating colorectal cancer in a subject in need of treatment, the method comprising co-administering to the subject:
a) a DKK1 antibody, or antigen binding-fragment thereof;
b) a VEGF or VEGFR inhibitor; and
c) optionally one or more chemotherapeutic agents
or a pharmaceutically acceptable salt of any of the foregoing, in an effective amount.

### Claim 2 (depends on 1)

The method of claim 1, wherein the VEGF or VEGFR inhibitor is selected from pazopanib, sunitinib, sorafenib, regorafenib, cabozantinib, lenvatinib, ponatinibcabozantinib, ziv-aflibercept, axitinibtivozanib, ramucirumab, vandetanib, or bevacizumab.

### Claim 3 (depends on 1)

The method of claim 1, wherein the VEGF or VEGFR inhibitor is bevacizumab or a biosimilar of bevacizumab.

### Claim 4 (depends on 3)

The method of claim 3, wherein the VEGF or VEGFR inhibitor is a biosimilar of bevacizumab selected from mvasi, zirabev, alymsys and vegzelma.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the DKK1 antibody is DKN-01.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the one or more chemotherapeutic agents is a fluorouracil-based chemotherapeutic selected from: 5-FU (fluorouracil), FOLFIRI, FOLFOX.

### Claim 7 (depends on 6)

The method of claim 6, wherein the FOLFOX is modified FOLFOX6.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, further comprising administration of one or more additional therapeutic agents selected from a PI3K inhibitor and/or an immune checkpoint inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immune checkpoint inhibitor is PD-1 inhibitor or a PD-L1 inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the PD-1 inhibitor is selected from nivolumab, pembrolizumab, pidilizumab, AMP-224, sasanlimab, spartalizumab, cemiplimab, retifanlimab, tislelizumab, camrelizumab, budigalimab, zimberelimab, and dostarlimab.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PD-1 inhibitor is pembrolizumab, nivolumab, tislelizumab, or budigalimab.

### Claim 12 (depends on 9)

The method of claim 9, wherein the PD-L1 inhibitor is selected from atezolizumab, durvalumab, avelumab, envafolimab, BMS-936559, lodapolimab, cosibelimab, sugemalimab and adebrelimab.

### Claim 13 (depends on 8)

The method of claim 8, wherein the PI3KCA inhibitor is selected from copanlisib, duvelisib, idelalisib and alpelisib.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the subject's colorectal cancer is determined to have a detectable level of tumoral DKK-1 expression.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the subject's plasma has a detectable level of DKK1.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the subject's serum has a detectable level of DKK1.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the subject has received one prior 5-FU based therapy for the colorectal cancer.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject's colorectal cancer is microsatellite stable (MSS).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject's colorectal cancer does not have a BRAF V600E mutation.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the subject's colorectal cancer is advanced colorectal cancer.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the subject's colorectal cancer is metastatic cancer.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the subject's colorectal cancer is an adenocarcinoma.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the treatment is administered in the course of one or more 14-day cycles.

### Claim 24 (depends on 23)

The method of claim 23, wherein 400 mg of the DKK1 antibody, or antigen binding-fragment thereof is administered on day 1 of the 14-day cycle.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein the VEGF inhibitor is bevacizumab and is administered at 5 mg/kg on day 1 of the 14-day cycle.

### Claim 26 (depends on 23, 24, 25)

The method of any one of claims 23-25, wherein the 14-day cycle is repeated.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein the DKK1 antibody, or antigen binding-fragment thereof, comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO: 1, LCDR2 has the amino sequence of SEQ ID NO: 2, LCDR3 has the amino sequence of SEQ ID NO:3, HCDR1 has the amino sequence of SEQ ID NO:4, HCDR2 has the amino sequence of SEQ ID NO:5, and an HCDR3 has the amino sequence of SEQ ID NO:6.

### Claim 28 (depends on 27)

The method of claim 27, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 7 and the HCVR comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 29 (depends on 27, 28)

The method of claim 27 or 28, wherein the LCVR and HCVR comprise amino acid sequences selected from the group consisting of: (i) a LCVR comprising the amino acid sequence of SEQ ID NO: 9 and a HCVR comprising the amino acid sequence of SEQ ID NO: 10; (ii) a LCVR comprising the amino acid sequence of SEQ ID NO: 11 and a HCVR comprising the amino acid sequence of SEQ ID NO: 12: (iii) a LCVR comprising the amino acid sequence of SEQ ID NO: 13 and a HCVR comprising the amino acid sequence of SEQ ID NO: 10; (iv) a LCVR comprising the amino acid sequence of SEQ ID NO: 14 and a HCVR comprising the amino acid sequence of SEQ ID NO: 10.

### Claim 30 (depends on 29)

The method of claim 29, wherein the LCVR comprises the amino acid sequence of SEQ ID NO: 11 and the HCVR comprises the amino acid sequence of SEQ ID NO: 12.

### Claim 31 (depends on 30)

The method of claim 30, wherein the DKK1 antibody comprises a heavy chain and a light chain amino acid sequence selected from the group consisting of a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and light chain comprising the amino acid sequence of SEQ ID NO: 16, b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a light chain comprising the amino acid sequence of SEQ ID NO: 18, c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 20, and d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 21.

### Claim 32 (depends on 31)

The method of claim 31, wherein the DKK1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 17 and a light chain comprising the amino acid sequence of SEQ ID NO: 18.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1-32, wherein the DKK1 antibody is DKN-01.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the subject is a human.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1-34, wherein the subject is a rapid progressor.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, wherein the subject harbors a mutation in a kRas gene or an nRas gene.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1-36, wherein the subject suffers from liver metastases.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 1-37, wherein the colorectal cancer is a rectal cancer.

### Claim 39

A pharmaceutical composition comprising:
a) a DKK1 antibody, or antigen binding-fragment thereof;
b) a VEGF or a VEGFR inhibitor; and
c) one or more chemotherapeutic agents or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 40

A pharmaceutical composition comprising:
a) a DKK1 antibody, or antigen binding-fragment thereof;
b) bevacizumab; and
c) one or more chemotherapeutic agents or a pharmaceutically acceptable salt of any of the foregoing.

### Claim 41

A kit comprising:
a) a DKK1 antibody, or antigen binding-fragment thereof;
b) a VEGF or a VEGFR inhibitor;
c) one or more chemotherapeutic agents or a pharmaceutically acceptable salt thereof; and
d) instructions for use.

### Claim 42

A kit comprising:
a) a DKK1 antibody, or antigen binding-fragment thereof;
b) bevacizumab;
c) one or more chemotherapeutic agents or a pharmaceutically acceptable salt thereof; and
d) instructions for use.
